Omada Health (OMDA) Q2 2026 Earnings Call Transcript
Omada Health (OMDA) reported Q2 2026 revenue of $88 million, up 43% year over year, with GAAP gross margin of 73% and GAAP net income of $5 million. Adjusted EBITDA was $11 million. The company raised full-year revenue guidance to $334 million to $340 million and adjusted EBITDA to $21 million to $27 million, citing member growth and lower cost to serve.
How this was made
The 30-second read
Why it matters
The key tradable update is the combination of record Q2 performance, expanded membership, and raised full-year revenue and adjusted EBITDA guidance, offset by explicit H2 moderation and GLP-1 coverage churn risk.
Market read
Guidance raise plus margin expansion is likely to drive re-rating, but the H2 growth moderation and GLP-1 coverage selectivity could limit upside and increase forecast-dispersion.
What to watch
Investors may underweight the CFO’s warning that YoY growth is expected to moderate in the second half and the CEO’s note that some employers are exiting GLP-1 coverage during current evaluation cycles.
Background
Omada is a virtual care platform monetizing chronic-condition programs, including GLP-1 Care Track, with growth tied to employer and payer coverage decisions.
Ticker impact
Omada reported Q2 2026 revenue of $88M (+43% YoY) and raised full-year revenue guidance to $334M-$340M plus adjusted EBITDA to $21M-$27M.
Near-term bias upward on guidance raise, with volatility risk if investors focus on H2 enrollment moderation and employer GLP-1 coverage churn.
The article discloses multiple fresh, decision-relevant datapoints: Q2 results, raised full-year guidance ranges, and explicit risk commentary about moderating YoY growth and some employers walking away from GLP-1 coverage.
Market effects
Reinforces demand and margin expansion for virtual chronic-care models tied to GLP-1 programs, while highlighting employer coverage selectivity risk.
HCSC covered-lives expansion adds incremental commercial distribution footprint for 2027.
Limited direct global spillover; primarily US commercial payer and employer benefit dynamics.
Counterpoint
The raised EBITDA guidance may be partially driven by cost-to-serve efficiency and cohort maturation, while GLP-1 coverage decisions could cap member growth in H2.
Key entities
- companyOmada Health, Inc.
Reported Q2 2026 results and raised full-year guidance; leadership transition announced for early 2027.
- executiveSean Duffy
CEO who will be succeeded by Wei-Li Shao on Jan. 1, 2027; discussed AI-driven care delivery and demand prediction.
- executiveWei-Li Shao
President who will become CEO on Jan. 1, 2027; highlighted AI reshaping personalized care and longer active treatment tenure.
- executiveSteve Cook
CFO who raised guidance and warned YoY growth is expected to moderate in the second half of 2026.
- customer/partnerHCSC
Health Care Service Corporation, referenced for covered-lives expansion for 2027.
